Head-to-head evidence
Risperidone (Risvan) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Ziprasidone
Marketed by Pfizer and partners
NCT00159770 · Phase 3 · completed
The study used randomization and active comparators but was open-label, with 290 participants, and its primary clinical endpoint was PANSS symptom change. No results are posted, so the primary endpoint cannot be classified as met or missed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Risperidone (Risvan)'s landscape · Ziprasidone's landscape